◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › T › TNDM

Tandem Diabetes Care Inc (TNDM) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · MEDICAL DEVICES · DATA UPDATED 2026-09-16

Tandem Diabetes Care Inc (TNDM) operates in the MEDICAL DEVICES industry and is headquartered in San Diego, United States with about 2,500 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, TNDM reported $1.0B in revenue and ($205M) in net income.

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system.

Interactive charts & full statements → Open the TNDM valuation workbench →

TNDM Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Total Revenue	$1.0B	$1.0B	$940M	$748M	$801M	$703M	$499M	$362M	$184M	$108M	$84M	$73M	$50M	$29M	$2M	—
Gross Profit	$583M	$531M	$490M	$368M	$413M	$376M	$261M	$194M	$90M	$44M	$24M	$27M	$15M	$6M	($1M)	—
Gross Margin %	56.0%	52.3%	52.1%	49.2%	51.5%	53.5%	52.2%	53.6%	48.9%	41.0%	28.0%	36.5%	30.7%	21.3%	-54.5%	—
Operating Income (EBIT)	($43M)	($78M)	($99M)	($233M)	($93M)	$23M	($8M)	($17M)	($45M)	($63M)	($78M)	($69M)	($76M)	($49M)	($33M)	($24M)
Operating Margin %	-4.1%	-7.7%	-10.5%	-31.2%	-11.6%	3.2%	-1.6%	-4.6%	-24.3%	-58.5%	-92.6%	-94.7%	-152.2%	-170.4%	-1335.4%	—
Net Income	($63M)	($205M)	($96M)	($223M)	($95M)	$16M	($34M)	($25M)	($123M)	($73M)	($83M)	($72M)	($80M)	($63M)	($33M)	($26M)
Net Margin %	-6.1%	-20.2%	-10.2%	-29.8%	-11.8%	2.2%	-6.9%	-6.8%	-66.7%	-67.9%	-99.1%	-99.4%	-159.9%	-217.7%	-1334.1%	—
EBITDA	($30M)	($175M)	($99M)	($196M)	($74M)	$34M	$2M	($11M)	($39M)	($56M)	($73M)	($64M)	($71M)	($55M)	($28M)	($23M)
Earnings Per Share (EPS)	$-0.93	$-3.04	$-1.47	$-3.43	$-1.47	$0.24	$-0.56	$-0.42	$-2.55	$-12.86	$-27.30	$-25.04	$-34.17	$-27.53	$-1,756.12	$-1,500.58
Shares Outstanding (M)	68M	67M	65M	65M	64M	64M	61M	59M	48M	6M	3M	3M	2M	2M	0M	0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TNDM Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$255M	$247M	$290M	$249M	$241M	$234M	$283M	$363M
Gross Profit	$145M	$137M	$167M	$134M	$126M	$118M	$157M	$125M
Gross Margin %	56.9%	55.3%	57.7%	53.9%	52.3%	50.5%	55.7%	34.3%
Operating Income (EBIT)	($14M)	($17M)	$8M	($20M)	($52M)	($121M)	($1M)	($26M)
Operating Margin %	-5.4%	-7.0%	2.9%	-8.1%	-21.5%	-51.6%	-0.2%	-7.2%
Net Income	($21M)	($20M)	($1M)	($21M)	($52M)	($131M)	$1M	($23M)
Net Margin %	-8.3%	-8.2%	-0.2%	-8.5%	-21.8%	-55.7%	0.3%	-6.4%
EBITDA	($9M)	($14M)	$11M	($19M)	($51M)	($116M)	$6M	($17M)
Earnings Per Share (EPS)	$-0.31	$-0.30	$-0.01	$-0.31	$-0.78	$-1.97	$0.01	$-0.35
Shares Outstanding (M)	68M	68M	68M	68M	67M	66M	66M	66M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TNDM Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Cash from Operations (CFO)	($6M)	($10M)	$24M	($32M)	$50M	$111M	$25M	$42M	($8M)	($66M)	($61M)	($59M)	($61M)	($48M)	($33M)	($22M)
Capital Expenditures (CapEx)	$21M	$20M	$19M	$27M	$34M	$24M	$32M	$20M	$3M	$6M	$9M	$6M	$5M	$6M	$6M	$1M
Free Cash Flow (FCF)	($27M)	($30M)	$5M	($59M)	$16M	$88M	($8M)	$22M	($11M)	($72M)	($70M)	($65M)	($66M)	($54M)	($39M)	($23M)
FCF Margin %	-2.6%	-2.9%	0.5%	-7.8%	2.0%	12.5%	-1.5%	6.2%	-6.2%	-66.8%	-83.2%	-88.7%	-132.7%	-185.4%	-1576.0%	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TNDM Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($35M)	$11M	$10M	$8M	($9M)	($18M)	$11M	$27M
Capital Expenditures (CapEx)	$4M	$6M	$7M	$4M	$6M	$3M	$3M	$5M
Free Cash Flow (FCF)	($39M)	$5M	$3M	$4M	($16M)	($21M)	$8M	$22M
FCF Margin %	-15.2%	1.9%	1.1%	1.7%	-6.5%	-9.1%	2.7%	5.9%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TNDM Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Total Assets	$1.2B	$881M	$968M	$953M	$1.1B	$905M	$716M	$326M	$206M	$95M	$112M	$125M	$106M	$162M	$40M	$14M
Cash & Cash Equivalents	$63M	$91M	$69M	$59M	$173M	$71M	$95M	$51M	$42M	$14M	$45M	$43M	$31M	$124M	$17M	$9M
Total Liabilities	$1.0B	$726M	$705M	$639M	$613M	$472M	$350M	$131M	$75M	$124M	$118M	$62M	$52M	$47M	$146M	$85M
Total Debt (Short + Long-Term)	$623M	$330M	$367M	$302M	$296M	$291M	$212M	$6M	$0M	$153M	$158M	$59M	$59M	$38M	$4M	$13M
Total Shareholders' Equity	$130M	$155M	$263M	$314M	$440M	$433M	$366M	$195M	$131M	($29M)	($6M)	$63M	$55M	$116M	($106M)	($71M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TNDM viewer.

Other Companies in MEDICAL DEVICES

NVCR · Novocure Ltd — $2 billion
ATEC · Alphatec Holdings Inc — $2 billion
CNMD · CONMED Corporation — $1 billion
IART · Integra LifeSciences Holdings — $1 billion
AORT · Artivion Inc — $1 billion
PRCT · Procept Biorobotics Corp — $1 billion
LMRI · Lumexa Imaging Holdings, Inc. Common Stock — $1 billion
IRMD · Iradimed Co — $1 billion

← TNC All “T” companies TNE →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.